A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer

חו"ל (דורש נסיעה)מגייס משתתפיםPHASE2

מצבים רפואיים

Metastatic Castration-resistant Prostate Cancer

סיכום בשפה פשוטהבעזרת בינה מלאכותית

הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.

מיקומים
  • Mayo Clinic, Phoenix, Arizona, United States

  • University of Arizona Cancer Center, Tucson, Arizona, United States

  • Arkansas Urology, Little Rock, Arkansas, United States

  • University of California-Davis, Sacramento, California, United States

  • Mayo Clinic, Jacksonville, Florida, United States

  • University of Miami, Miami, Florida, United States

  • Moffitt Cancer Center, Tampa, Florida, United States

  • University of Chicago, Chicago, Illinois, United States

  • Duly Health, Lisle, Illinois, United States

  • Wichita Urology, Wichita, Kansas, United States

  • Willis Knighton, Shreveport, Louisiana, United States

  • Michigan Institute of Urology, Troy, Michigan, United States

  • Mercy Hospital, St Louis, Missouri, United States

  • University of Nebraska Medical Center, Omaha, Nebraska, United States

  • Northwell Health, Lake Success, New York, United States

  • NYU Langone, New York, New York, United States

  • Weill Cornell, New York, New York, United States

  • Ohio State University, Columbus, Ohio, United States

  • Thomas Jefferson University, Philadelphia, Pennsylvania, United States

  • University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

  • Houston Metro Urology, Houston, Texas, United States

  • Summit Urology, Murray, Utah, United States

  • Medical College of Wisconsin, Milwaukee, Wisconsin, United States

מובילי המחקר
  • Stephen Dale, MD

    Study Director

    Syncromune, Inc.